Gilead Sciences Inc - Company Profile
Powered by 
All the sales intelligence you need on Gilead Sciences Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Gilead Sciences Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Gilead Sciences Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View moreGilead Sciences Inc (Gilead) is a biopharmaceutical company focused on discovering, developing, and delivering innovative medicines. The company's main activities include advancing therapies for life-threatening diseases such as human immunodeficiency virus (HIV) infection; Covid-19; liver diseases such as hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, primary biliary cholangitis; cancer; and inflammation related to rheumatology; pulmonology; dermatology; hepatology; and gastroenterology. Gilead markets its products through commercial teams, third-party distributors, and corporate partners. The company offers its products to physicians, hospitals, clinics, and other healthcare providers through brands such as Biktarvy, Genvoya, and Trodelvy. It operates through subsidiaries in Europe, the Americas, Asia-Pacific, the Middle East, and Africa. Gilead is headquartered in Foster City, California, the US.
Headquarters
United States of America
Address
333 Lakeside Drive, Foster City, California, 94404
Website
www.gilead.com
Telephone
1 650 5743000
No of Employees
17,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GILD (NASD)
Revenue (2024)
$29.4B
6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-91.5%
(2024 vs 2023)
Market Cap*
$160.9B
Net Profit Margin (2023)
XYZ
-92.0%
(2024 vs 2023)
* As of and is in US$
Gilead Sciences Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| HIV/AIDS: | AmBisome |
| Atripla | Atripla |
| Biktarvy | Biktarvy |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Acquisitions/Mergers/Takeovers | In April, the company acquired Arcellx, Inc. |
| 2026 | Contracts/Agreements | In April, the company entered into an agreement to acquire Tubulis GmbH, a clinical-stage biotech company. |
| 2026 | Contracts/Agreements | In March, the company entered into an agreement to acquire Ouro Medicines, a biotech company. |
Competitor Comparison
| Key Parameters | Gilead Sciences Inc | Merck & Co Inc | Pfizer Inc | Novartis AG | Abbott Laboratories |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Switzerland | United States of America |
| City | Foster City | Rahway | New York City | Basel | Abbott Park |
| State/Province | California | New Jersey | New York | Basel-Stadt | Illinois |
| No. of Employees | 17,000 | 75,000 | 75,000 | 75,267 | 115,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Daniel P. O’Day | Chairman; Chief Executive Officer | Executive Board | 2019 | 61 |
| Andrew D. Dickinson | Chief Financial Officer | Senior Management | 2016 | 56 |
| Dietmar Berger, M.D, Ph.D | Chief Medical Officer | Senior Management | 2025 | 63 |
| Johanna Mercier | Chief Commercial Officer | Senior Management | 2019 | 56 |
| Jyoti Mehra | Executive Vice President - Human Resources | Senior Management | 2019 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer